Dental records do more than document procedures, they track progress across every stage of care. MTS AI-driven #dentistrytranscriptionservice ensures treatment notes, procedures, and plans are clearly captured within HIPAA-compliant workflows.
Well-documented records help maintain continuity and support better patient outcomes.
One to six in 1,000 children in the United States are born with severe to profound hearing loss.1 For a parent, that diagnosis can be life altering, and they are in need of help, information and support. Today, Cochlear Limited (ASX: COH), the global leader in implantable hearing solutions, introduces IWantYouToHear.com as part of its ongoing commitment to parents seeking treatment options for their child’s severe to profound hearing loss.
For many parents with a child who has received a hearing loss diagnosis, the wish for their child is immediate and clear: “I want you to hear.” They want their child to hear the birds and their favorite songs, learn to develop speech and language, and most of all, they want their child to hear them say “I love you.”
To view the multimedia release go to:
http://www.multivu.com/players/English/7658351-cochlear-americas-i-want-you-to-hear/
LUNGevity, the nation’s leading lung cancer-focused nonprofit organization today launched a new mobile application designed to make understanding and living with lung cancer less daunting and considerably more manageable. The new Lung Cancer Navigator mobile app provides lung cancer patients with access to the latest medical and treatment information related to their specific lung cancer diagnosis, and serves as a convenient hub for organizing customized care and support networks, asking questions, describing and tracking symptoms, and managing multiple medications.
To view the multimedia release go to:
http://www.multivu.com/players/English/7865551-lungevity-lung-cancer-navigator-app/
Galderma, a leading global pharmaceutical company exclusively focused on dermatology, today announced that the European Commission has granted Marketing Authorisation in Europe for Mirvaso® (brimonidine) 3 mg/g gel.
Mirvaso® is an alpha-2 adrenergic receptor agonist that acts rapidly and can last for up to 12 hours.1 It is indicated for the symptomatic treatment of facial erythema (redness) of rosacea in adult patients.
To view the Multimedia News Release, go to http://www.multivu.com/mnr/65011-mirvaso-first-and-only-treatment-rosacea
Miramar Labs today announced that the miraDry System for the treatment of primary axillary hyperhidrosis, commonly known as excessive underarm sweat, is now available to select physicians in the U.S. The miraDry procedure provides a safe and lasting solution for this debilitating condition.
The U.S. Food & Drug Administration granted clearance for miraDry following a robust, randomized, blinded clinical study that involved 120 patients at seven clinics and followed them 12-months post treatment. The miraDry System delivers energy non-invasively to the area under the arm where the sweat glands reside which creates localized heat to destroy and eliminate the glands. Since sweat glands do not regenerate, results are lasting.
To view Multimedia News Release, go to http://www.multivu.com/mnr/54021-miramar-labs-miradry-treat-excessive-underarm-sweat-axillary-hyperhidrosis
The Oral Cancer Foundation is pleased to have developed partnerships with two highly visible Hollywood stars to raise awareness of a disease of which too few people in the U.S. have ever heard. Academy Award winning actor, Michael Douglas, who has recently completed successful treatment for an advanced oral cancer, and Emmy and Tony Award winning actress, Blythe Danner, who lost her husband to the same disease have partnered with OCF to send a very important message about screening and early detection of oral cancer to the American public.
To view Multimedia News Release, go to http://www.multivu.com/mnr/57170-oral-cancer-foundation-michael-douglas-early-detection-psa-campaign
They stand out in a crowd. They have more fun. They always steal the spotlight. Blondes are a special breed—and they deserve special treatment. That’s why the John Frieda® Sheer Blonde® team is proud to appoint June as Blonde Appreciation Month—a time to celebrate what sets blondes apart and equip them with the expert care they need to preserve their signature shade.
To view the Multimedia News Release, go to http://www.multivu.com/mnr/61555-megan-hilty-joins-john-frieda-sheer-blonde-hair-care
Boston Scientific (NYSE: BSX) has received U.S. Food and Drug Administration (FDA) approval for the SYNERGY™ Bioabsorbable Polymer Drug-Eluting Stent System (BP-DES) for the treatment of coronary artery disease.
With this FDA approval, Boston Scientific will commence commercialization of the first and only BP-DES in the U.S. Notably, both the drug coating and the polymer – which modulates drug release – are fully absorbed shortly after drug elution is complete at three months.
The SYNERGY Stent provides synchronized drug and polymer absorption. It is designed to enable more rapid and complete arterial healing, and to thereby reduce the risk of complications associated with long-term polymer exposure compared to currently-used drug-eluting stents (DES) with permanent polymers.
To view the multimedia release go to:
http://www.multivu.com/players/English/7223456-boston-scientific-fda-approval-synergy/
Nu Skin Enterprises, Inc. (NYSE: NUS) today announced the consumer launch of ageLOC LumiSpa, the first-of-its-kind, dual-action skin care device that treats and cleanses the skin. Following successful market previews, ageLOC LumiSpa is now available in the Americas and EMEA regions with launches to follow in North Asia, Greater China and Southeast Asia over the next three months.
ageLOC LumiSpa simultaneously delivers a skin-perfecting treatment and superior cleansing benefits to reveal smoother, softer skin after just one use. Now Nu Skin customers can be confident that their skin is clean, radiant and always ready for the perfect selfie or spontaneous photo moment.
To view the multimedia release go to:
https://www.multivu.com/players/English/8239151-nu-skin-care-device-ageloc-lumispa/
More than 80,000 healthcare workers and their communities from across the country and around the world joined together in the Medline Pink Glove Dance for breast cancer online video competition. After a hard-fought dance battle, the online votes are in and Medline is pleased to name Geisinger Health System, Danville, Pa., as the winner. As a result, $25,000 will be donated to their charity of choice, the American Cancer Society, providing free transportation for treatment to central Pennsylvania breast cancer patients in need. Additionally, Medline and participating hospitals will donate another $1 million to the National Breast Cancer Foundation and various local breast cancer charities nationwide. More than $2.2 million has been donated through the campaign and Medline Foundation since 2005.
To view the Multimedia News Release, go to http://www.multivu.com/mnr/64450-medline-pink-glove-dance-video-competition-winners-breast-cancer-education
Are You Suffering from hemorrhoids that don't want to go away? Hemorrhoids are unpleasant and worrisome. Getting rid of hemorrhoids can be difficult. And, you don’t want to strain when having a bowel movement, otherwise they will get bigger. But, do you know if you have hemorrhoids? Do you have some of these symptoms?
To mark National Massage Therapy Awareness Week (NMTAW), October 20-26, the American Massage Therapy Association (AMTA) has compiled research that suggests symptoms of stress, anxiety and depression (all associated with mental health) may be alleviated with massage therapy.
To view Multimedia News Release, go to http://www.multivu.com/mnr/63936-amta-massage-therapy-research-roundup-mental-health-benefits
